Literature DB >> 23812148

Results of cement versus bone graft reconstruction after intralesional curettage of bone tumors in the skeletally immature patient.

Matthew T Wallace1, Robert M Henshaw.   

Abstract

BACKGROUND: Resection of periphyseal tumors in children presents several unique challenges and complications. Injury to the adjacent physis during resection and adjuvant application has been associated with adverse growth-related outcomes including angular deformities and physeal arrest. The appropriate method of reconstructing bone defects after resection is also controversial. To date there is scant literature on the use of polymethylmethacrylate (PMMA) bone cement as a method of reconstruction in children, and few long-term studies exist on the incidence of growth-related complications after reconstruction. The objective of this study is to evaluate the mechanical, oncological, and developmental outcomes of PMMA use in children.
METHODS: The authors retrospectively reviewed the medical records and radiographs of 36 skeletally immature patients who underwent intralesional resections of locally aggressive bone tumors. These patients were divided into 17 patients who received reconstruction with PMMA cement, and 19 patients who were reconstructed with bone graft. Follow-up clinical and radiographic evaluations performed after skeletal maturity were reviewed to assess the structural durability, local tumor recurrence rates, reoperation rates, and the incidence of postoperative complications such as deformity, adjacent joint arthrosis, growth arrest, pain, and functional limitation.
RESULTS: The average patient age at the time of surgery was 11.79 years (range, 6 to 15 y). The average length of patient follow-up was 5.3 years (range, 2 to 11.5 y). There were no statistically significant differences observed in the rates of reoperation, local tumor recurrence, growth-related complications, adjacent joint arthrosis, or postoperative pain between the 2 groups. There were no postoperative fractures in the cement group, compared to 3 fractures in the bone graft group, although this was not statistically significant.
CONCLUSIONS: PMMA cement as a structural augment after resection may be used in the pediatric population for improving the mechanical stability of bone. Cement use is associated with complication rates of arthrosis, local recurrence, and growth complications comparable to those observed with bone grafting. LEVEL OF EVIDENCE: Level III: Retrospective comparison study.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23812148     DOI: 10.1097/BPO.0b013e31829b2f61

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  5 in total

1.  Treatment of bone defect with calcium phosphate cement subsequent to tumor curettage in pediatric patients.

Authors:  Tomoki Nakamura; Akihiko Matsumine; Kunihiro Asanuma; Takao Matsubara; Akihiro Sudo
Journal:  Oncol Lett       Date:  2015-11-02       Impact factor: 2.967

Review 2.  Current management of aneurysmal bone cysts.

Authors:  Howard Y Park; Sara K Yang; William L Sheppard; Vishal Hegde; Stephen D Zoller; Scott D Nelson; Noah Federman; Nicholas M Bernthal
Journal:  Curr Rev Musculoskelet Med       Date:  2016-12

3.  Arthroscopic management of Juxta-articular chondroblastoma with bone substitutes - A case report.

Authors:  Prashant Upendra Acharya; Kiyana Mirza
Journal:  J Clin Orthop Trauma       Date:  2022-05-11

4.  Risk factors of fracture following curettage for bone giant cell tumors of the extremities.

Authors:  Shinji Tsukamoto; Andreas F Mavrogenis; Manabu Akahane; Kanya Honoki; Akira Kido; Yasuhito Tanaka; Davide Maria Donati; Costantino Errani
Journal:  BMC Musculoskelet Disord       Date:  2022-05-19       Impact factor: 2.562

5.  'Umbrella construct' - an innovative technique for reconstruction of the proximal humerus after curettage in locally aggressive benign bone tumours.

Authors:  Ashish Gulia; Ajay Puri; Srinath Gupta; Vineet Kurisunkal
Journal:  Shoulder Elbow       Date:  2020-01-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.